Komal Malik

Komal Malik

Auto-generated profile, based on publicly available information

Komal Malik

Department of Internal Medicine, Mutua Terrassa Hospital

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
JSJosé Sanz-Santos
José Sanz-Santos
Pere AlmagroPere Almagro
Pere Almagro
KMKomal Malik
Komal Malik
Pablo Martinez-CamblorPablo Martinez-Camblor
Pablo Martinez-Camblor
CCConxi Caro
Conxi Caro
RRRamón Rami-Porta
Ramón Rami-Porta
Rationale: Current guidelines for non–small cell lung cancer (NSCLC) mediastinal staging recommend starting invasive staging with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). However, the indication to confirm a negative result of EBUS-TBNA by means of video-assisted mediastinoscopy (VAM) before resection differs in every guideline. Objectives: Our aim was to evaluate the current evidence regarding the added value of confirmatory VAM after a negative EBUS-TBNA result for mediastinal staging in patients with NSCLC. Methods: Systematic searches of studies on EBUS-TBNA for NSCLC mediastinal staging with or without confirmatory VAM but with surgical confirmation of negative results were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement in PubMed, SCOPUS, the Cochrane Library, and guidelines from 2005 through November 2021. In the meta-analysis, the sensitivity of confirmatory VAM after a negative EBUS-TBNA result, as well as the sensitivity and negative predictive value of the combination EBUS-TBNA plus confirmatory VAM, alongside the number of confirmatory VAMs required to detect additional N2/3 disease (number needed to treat [NNT]), in patients with a previous negative EBUS-TBNA result were estimated. Results: A total of 5,412 articles were found, of which 29 studies were included. Random effects meta-analysis showed a sensitivity of 66.9% (95% confidence interval [CI], 55.8–77.1%) for confirmatory VAM, and 96.7% (95% CI, 95.1–98%) for the combination EBUS-TBNA plus confirmatory VAM. Negative predictive value in studies with confirmatory VAM increased of 79.2% (95% CI, 71.4–86.1%) for EBUS-TBNA alone to 91.8% (95% CI, 87.1–95.5%) for EBUS-TBNA plus confirmatory VAM. The NNT of confirmatory VAM in patients with a previous negative EBUS-TBNA result was 23.8 (95% CI, 19.3–31.2). Conclusions: Confirmatory VAM after negative EBUS-TBNA reduces the rate of unforeseen N2/3 disease, but with a high NNT, and it should be recommended only for certain cases yet to be defined.

1 October 2017 in EP Europace
Verified
Journal Article
Open access
PDF file
ASA Sotiriou
A Sotiriou
HPHc Patel
Hc Patel
STSara Tyebally
Sara Tyebally
SRS Raza
S Raza
TQT Qudah
T Qudah
CHC Hayward
C Hayward
Introduction: Implantable cardioverter-defibrillators (ICDs) have international guideline endorsement as a therapy to reduced sudden cardiac death in patients with severe systolic cardiac dysfunction. However, their role in octogenarians is uncertain. We sought to describe current practice pertaining to octogenarians and ICD implantation at a tertiary referral centre.